Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma
- PMID: 6845404
- DOI: 10.1097/00007691-198303000-00008
Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma
Abstract
High-performance liquid chromatographic assays for propranolol and its major metabolites in plasma and breast milk are described. The breast milk/whole plasma ratios of propranolol in three lactating women were in the range of 0.33 to 1.65. The half-life of elimination of propranolol from breast milk was 6.5 +/- 3.4 h (mean +/- SD), which was significantly longer (t = 1.844, df = 4, p less than 0.01) than the half-life of elimination of propranolol from plasma, which was 2.6 +/- 1.2 h (mean +/- SD). The half-life of elimination of the propranolol metabolite naphthoxylactic acid from breast milk was 4.2 +/- 0.9 h (mean +/- SD), which was not significantly different (t = 0.042, df = 4, p greater than 0.05) from the mean half-life of elimination from plasma, which was 4.2 +/- 1.2 h (mean +/- SD). The penetration of propranolol glucuronide into breast milk was slower and to a lesser extent than that of propranolol and naphthoxylactic acid. The maximum dose, calculated from the results presented in this paper, ingested as either propranolol or as propranolol glucuronide in breast milk by the neonate would be less than 0.1% of the maternal dose.
Similar articles
-
Metabolism of propranolol in the human maternal-placental-foetal unit.Eur J Clin Pharmacol. 1983;24(6):727-32. doi: 10.1007/BF00607078. Eur J Clin Pharmacol. 1983. PMID: 6884410 Clinical Trial.
-
Propranolol in pregnancy three year prospective study.Clin Exp Hypertens B. 1983;2(2):341-50. doi: 10.3109/10641958309006092. Clin Exp Hypertens B. 1983. PMID: 6872291 Clinical Trial.
-
Measurement of naphthoxylactic and naphtoxyacetic acid in human plasma following propranolol administration.Res Commun Chem Pathol Pharmacol. 1979 Feb;23(2):279-86. Res Commun Chem Pathol Pharmacol. 1979. PMID: 461953
-
The effect of medications on the lactating mother and her infant.Clin Obstet Gynecol. 1980 Dec;23(4):1073-80. doi: 10.1097/00003081-198012000-00010. Clin Obstet Gynecol. 1980. PMID: 6160936 Review.
-
Pharmacokinetics of propranolol: a review.Postgrad Med J. 1976;52 Suppl 4:22-25. Postgrad Med J. 1976. PMID: 787953 Review.
Cited by
-
Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).Clin Pharmacokinet. 1988 Apr;14(4):189-216. doi: 10.2165/00003088-198814040-00001. Clin Pharmacokinet. 1988. PMID: 3292100 Review.
-
The Risk for Neonatal Hypoglycemia and Bradycardia after Beta-Blocker Use during Pregnancy or Lactation: A Systematic Review and Meta-Analysis.Int J Environ Res Public Health. 2022 Aug 4;19(15):9616. doi: 10.3390/ijerph19159616. Int J Environ Res Public Health. 2022. PMID: 35954977 Free PMC article.
-
Risk for neonatal hypoglycaemia and bradycardia after beta-blocker use during pregnancy or lactation: a systematic review and meta-analysis protocol.BMJ Open. 2022 Aug 25;12(8):e055292. doi: 10.1136/bmjopen-2021-055292. BMJ Open. 2022. PMID: 36008071 Free PMC article.
-
Metabolism of propranolol in the human maternal-placental-foetal unit.Eur J Clin Pharmacol. 1983;24(6):727-32. doi: 10.1007/BF00607078. Eur J Clin Pharmacol. 1983. PMID: 6884410 Clinical Trial.
-
Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.Eur J Clin Pharmacol. 1983;25(4):481-90. doi: 10.1007/BF00542115. Eur J Clin Pharmacol. 1983. PMID: 6653642 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous